Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Rohto Pharmaceutical Co's Enterprise Value is 円541,997 Mil.
Rohto Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円0 Mil. Therefore, Rohto Pharmaceutical Co's EV-to-FCF for today is .
The historical rank and industry rank for Rohto Pharmaceutical Co's EV-to-FCF or its related term are showing as below:
TSE:4527'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 25.61
Current: 25.61
During the past 13 years, the highest EV-to-FCF of Rohto Pharmaceutical Co was 25.61. The lowest was 0.00. And the median was 0.00.
TSE:4527's EV-to-FCF is ranked worse than 68.49% of 1190
companies
in the Consumer Packaged Goods industry
Industry Median: 16.105
vs TSE:4527: 25.61
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rohto Pharmaceutical Co (TSE:4527) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rohto Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Rohto Pharmaceutical Co's share price for today is 円2435.00.
Rohto Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円145.290.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Rohto Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rohto Pharmaceutical Co EV-to-FCF vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Rohto Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Rohto Pharmaceutical Co's EV-to-FCF falls into.
Rohto Pharmaceutical Co's current Enterprise Value is 円541,997 Mil.
Rohto Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Rohto Pharmaceutical Co (TSE:4527) Overvalued in 2026?
Based on GuruFocus' analysis, Rohto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円2,435.00 is trading 30% below its estimated GF Value™ of 円3,477.35.
GuruFocus considers Rohto Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for TSE:4527:
EV-to-FCF:
GF Value™: 円3,477.35 vs. price of 円2,435.00 (30% below fair value)
No single metric tells the full story. See the TSE:4527 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rohto Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of health and beauty care products. The company operates through four reportable segments: Japan, America, Europe, and Asia. Each segment manufactures and sells products related to eye care (such as eye drops and eyewash), skin care (including dermatological medications, lip balm, sunscreen, and functional cosmetics), oral medication (such as gastrointestinal and herbal medicines, and supplements), and other products such as in-vitro diagnostic reagents. It generates the majority of its revenue from Japan.
92GF Score
Get the complete analysis for TSE:4527
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4527 has been successfully added to your 
